In patients with type 1 diabetes (T1D), sodium-glucose cotransporter 2 (SGLT2) inhibitors plus glucagon receptor antagonists (GRAs) may improve glycemic control, reduce insulin use, and mitigate ...

New insights into the underlying mechanisms of Type 2 diabetes and novel potential therapeutic targets for the disease were revealed in a recent study by a team of Texas A&M AgriLife Research ...

Glucagon-like peptide-1 (GLP-1) is a hormone secreted after eating to stimulate insulin release and suppress glucagon, a ...

In a recent article published in Science, researchers reviewed clinical studies on the advantages of glucagon-like peptide-1 (GLP-1) medicines beyond glycemic and weight control. GLP-1 medications, ...

A new study has uncovered a critical role for the enzyme Glucose-6-phosphatase 2 (G6PC2) in regulating blood sugar levels. The research sheds new light on how this enzyme influences glucagon secretion ...

Add Yahoo as a preferred source to see more of our stories on Google. Alpha cells in the pancreas produce GLP-1, reshaping our understanding of blood sugar control and diabetes care. (CREDIT: ...

New findings raise the possibility of promising therapeutic strategies for the management of hypoglycemia in type 1 diabetes patients. Study: Loss of electrical β-cell to δ-cell coupling underlies ...

Pre-clinical studies demonstrated that blocking glucagon activity can improve heart function in heart failure with preserved ejection fraction (HFpEF), a type of heart disease that is notoriously ...

People with diabetes take insulin to lower high blood sugar. However, if glucose levels plunge too low—from taking too much insulin or not eating enough sugar—people can experience hypoglycemia, which ...

Wanbao Yang, Ph.D., (left) graduate student and the study’s first author, and Shaodong Guo, Ph.D., who served as its principal investigator. (Texas A&M AgriLife photo by Tyler Morales) The study, ...